Marshall Wace’s Summit Therapeutics SMMT Stock Holding History

Marshall Wace’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.01M	Buy	+475,241	New	+$7.69M	0.01%	1028
2025 Q3	–	Sell	-271,641	Closed	-$5.78M	–	3360
2025 Q2	$5.78M	Buy	+271,641	New	+$6.19M	0.01%	1071
2023 Q2	–	Sell	-214,033	Closed	-$375K	–	2933
2023 Q1	$375K	Sell	214,033 -408,833	-66%	-$1.12M	﹤0.01%	2217
2022 Q4	$2.65M	Buy	622,866 +482,206	+343%	+$877K	0.01%	1576
2022 Q3	$167K	Buy	+140,660	New	+$159K	﹤0.01%	3123

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Marshall Wace's SMMT Position: Q1 2026 in Review

Marshall Wace opened a new position in Summit Therapeutics (SMMT) in Q1 2026: 475,241 shares worth $9.01M. The stake represents 0.01% of the portfolio and ranks #1028 among its holdings. This is a return to the name: Marshall Wace previously reported a position in SMMT as recently as Q2 2025.

Marshall Wace first reported a position in SMMT in Q3 2022 and has held it in 5 quarters since. 222 funds tracked by Wall St. Rank hold SMMT as of Q1 2026.

Marshall Wace held 475,241 shares of Summit Therapeutics worth $9.01M as of Q1 2026.
Summit Therapeutics was a new Marshall Wace position in Q1 2026.
Summit Therapeutics made up 0.01% of Marshall Wace's portfolio in Q1 2026, its #1028 holding.
Marshall Wace first reported a position in Summit Therapeutics in Q3 2022 and has held it in 5 quarters since.
222 funds tracked by Wall St. Rank held Summit Therapeutics as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.